Skip to content
Screener

Merck & Co. MRK EPS (Diluted)

EPS (Diluted) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.62+153%
Pfizer logo
PfizerPFE
-$0.04-108%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$2.27-0.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$12.23-4.5%
Cytokinetics logo
CytokineticsCYTK
-$1.50-33.9%
Phibro Animal Health Corporation logo
Phibro Animal Health CorporationPAHC
$0.53+23.3%

Other financials

Income statement

See full
Revenue$16.6B+5.1%
Gross profit$12.2B-0.3%
Net income-$1.3B-130%

Balance sheet

See full
Cash & equivalents$6.9B-14.6%
Total debt$56.7B+54.0%
Total equity$41.9B-14.4%
Total assets$129.80B+10.4%

Cash flow

See full
Operating cash flow$5.4B+63.1%
CapEx$893.0M+16.9%
Free cash flow$4.5B+77.0%

Valuation

See full
Market cap$377.72B+79.9%
Enterprise value$427.56B+79.1%
P/E119×+106×
P/S5.7×+2.4×

Profitability

See full
Gross margin73%-3.6pp
Net margin4.8%-21.0pp
FCF margin24.1%+1.0pp

Returns & leverage

See full
Return on equity7%-28.5pp
Debt / equity1.4×+0.6×
Current ratio1.3×-0.1×

Where this comes from

Reported directly by Merck & Co. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Merck & Co.’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 4:11 PM EDT
Fiscal quarter
Q3 FY2028
Calendar quarter
Q3 2028
Accession
0000310158-26-000212
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
17,29010,80737,11020,433
(Loss) Income Before Taxes(683)4,999(4,217)10,902
Income Tax Provision6545711,3631,388
Net (Loss) Income(1,337)4,428(5,580)9,514
Less: Net (Loss) Income Attributable to Noncontrolling Interests(2)1(5)8
Net (Loss) Income Attributable to Merck & Co., Inc.$(1,335)$4,427$(5,575)$9,506
Basic (Loss) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders$(0.54)$1.76$(2.26)$3.78
(Loss) Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders$(0.54)$1.76$(2.26)$3.77

Item 1. Financial Statements

FAQ

What is Merck & Co.'s EPS (diluted)?
Merck & Co. (MRK) reported EPS (diluted) of -$0.54 in Q2 2026.
How has Merck & Co.'s EPS (diluted) changed year-over-year?
Merck & Co.'s EPS (diluted) decreased by 130.7% year-over-year, from $1.76 to -$0.54.
What is the long-term trend for Merck & Co.'s EPS (diluted)?
Over 3 years (2021 to 2025), Merck & Co.'s EPS (diluted) has grown at a 12.4% compound annual growth rate (CAGR), from $5.14 to $7.29.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Merck & Co.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude